CABA Cabaletta Bio, Inc.: Forward P/S Multiple
Cabaletta Bio, Inc. (CABA) is developing its cutting-edge CARTA cell therapy to combat autoimmune pathologies. The forward price-to-sales ratio reflects these extensive R&D investments, with its value stabilizing at . High clinical expectations and investor confidence reinforce the company's status as a leader in CAR-T application. A strategic alliance with the University of Pennsylvania enables the synthesis of academic expertise with its own proprietary innovations.
Metric breakdowns and analytics for Cabaletta Bio Inc (CABA)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- debt level and financial liquidity data:
Total Debt to Capital Cabaletta Bio, Inc.|CABA - Long-Term Debt to Capital|Short-Term Debt to Equity Cabaletta Bio, Inc.|CABA - Company Debts|Debts to Book Capitalization Cabaletta Bio Inc|CABA - Long-Term Debt|Company Current Liabilities Cabaletta Bio, Inc.|Quick Liquidity Indicator cabalettabio.com
- financial results and valuation multiples details:
CABA - Profit After Payment of Taxes|Projected Future Earnings Cabaletta Bio, Inc.|CABA - P/E Multiple|Projected Price to Earnings Cabaletta Bio, Inc|CABA - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Cabaletta Bio Inc|CABA - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Cabaletta Bio, Inc.|CABA - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months cabalettabio.com|CABA - Earnings per share growth rate in current year|Expected earnings per share growth for next year Cabaletta Bio, Inc.
- total revenue and sales volume data:
Summary company analytics:Cabaletta Bio CABA
A conservative investor assesses the fundamental stability of Cabaletta Bio, Inc. (CABA) through the balance of market value and expected cash flows. This metric correlates current capitalization with projected revenue; therefore, the company's forward P/S chart helps determine the degree of asset overheating relative to the commercialization potential of cell therapies developed through strategic alliances and the acquisition of promising biotech laboratories.
Competitor analysis
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|ADMA Corp (ADMA) - Forward Price-to-Revenue Multiple|PTGX: Forward P/S Multiple|immunovant.com (IMVT) - Forward P/S Multiple|KNSA (Kiniksa) - Forward P/S Multiple|Price-to-Projected Revenue Ratio GRFS|Forward P/S Multiple ADPT|Forward P/S Multiple Celldex Corp (CLDX)|Price-to-Projected Revenue Ratio Aurinia Pharmaceuticals AUPH|biocryst.com - Price-to-Projected Revenue Ratio|Vera Therapeutics - Forward P/S Multiple|Market Cap to Future Revenue Ratio Dianthus Therapeutics Inc|PHVS (Pharvaris Corp) - Forward Price-to-Revenue Multiple|ABCL: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple TRML|PGEN (precigen.com) - Price to Expected Revenue Ratio|Forward P/S Multiple PHAR|Forward P/S Multiple Nektar Therapeutics Inc (NKTR)|Upstream Bio Corp - Forward Price-to-Revenue Multiple|Forward Price to Sales ZBIO|Immunome, Inc. - Forward P/S Multiple|GOSS: Price-to-Projected Revenue Ratio|KALV: Forward P/S Multiple|SEPN - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Pieris Pharmaceuticals Inc|Market Cap to Future Revenue Ratio Savara Pharma SVRA|Forward Price-to-Revenue Multiple RIGL (Rigel Pharmaceuticals)|ANAB (anaptysbio.com) - Forward Price to Sales|Forward P/S Multiple ATXS (Astria Therapeutics, Inc.)|Market Cap to Expected Sales Ratio enGene Holdings Inc (ENGN)|RAPT - Price-to-Projected Revenue Ratio|JBIO (Aerovate Therapeutics Inc) - Market Cap to Projected Revenue|ACRS: Forward P/S Multiple|Forward Price-to-Revenue Multiple kyvernatx.com|Forward Price-to-Revenue Multiple TLSA|Ventyx Biosciences Inc. (VTYX) - Market Cap to Expected Sales Ratio|Forward P/S Multiple THTX|Forward Price-to-Revenue Multiple Avalo Therapeutics Inc AVTX|Forward P/S Multiple ELDN (Eledon Pharmaceuticals)|Forward P/S Multiple agenusbio.com AGEN|Climb Bio - Forward P/S Multiple|ZURA: Price-to-Projected Revenue Ratio|ATYR: Forward P/S Multiple|Adagene Inc. (ADAG) - Forward P/S Multiple|Price-to-Projected Revenue Ratio ImageneBio|Shattuck Therapeutics - Future Price to Revenue|Forward P/S Multiple EQ|CNTB (connectbiopharm.com) - Forward Price to Sales|Forward P/S Multiple IMUX (Immunic)|Forward P/S Multiple Atara Biotherapeutics, Inc. ATRA|IFRX - Price-to-Projected Revenue Ratio|Forward Price to Sales XFOR (x4pharma.com)|adicetbio.com (ACET) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Celularity|INMB (INmune Bio Corp) - Forward P/S Multiple|Forward P/S Multiple Barinthus Biotherapeutics Corp|Forward Price-to-Revenue Multiple KZR (Kezar Life Sciences)|SABS (sabbiotherapeutics.com) - Forward Price to Sales|Forward P/S Multiple AKTX (Akari Therapeutics Plc)|Market Cap to Expected Sales Ratio Enlivex Therapeutics Ltd (ENLV)|QTTB - Price-to-Projected Revenue Ratio|GeoVax Corp (GOVX) - Forward Price-to-Revenue Multiple|Edesa Biotech, Inc. (EDSA) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple ibioinc.com|Forward Price-to-Revenue Multiple CARM|Forward P/S Multiple XTL Biopharmaceuticals Ltd|Price-to-Projected Revenue Ratio Bolt Biotherapeutics (BOLT)|hcwbiologics.com - Market Cap to Projected Revenue|Forward P/S Multiple APVO (Aptevo Therapeutics Inc.)|AIM ImmunoTech, Inc. (AIM) - Market Cap to Future Revenue Ratio|Aditxt Corp - Forward P/S Multiple|GRI Bio Inc (GRI) - Forward Price-to-Revenue Multiple|XRTX: Forward P/S Multiple|Vyome Therapeutics (HIND) - Forward P/S Multiple|REVB (Revelation Biosciences) - Forward P/S Multiple|Price-to-Projected Revenue Ratio INDP|Forward P/S Multiple SCNI|Forward P/S Multiple calcimedica.com (CALI)|Price-to-Projected Revenue Ratio Affimed N.V. AFMD|Allakos Inc - Price-to-Projected Revenue Ratio|HOOKIPA - Forward P/S Multiple|Market Cap to Future Revenue Ratio IGM Biosciences, Inc.|ITOS (iTeos Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|OCEA: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple TCBP|THRD (Third Harmonic Bio Inc) - Price to Expected Revenue Ratio
